Health Condition 1: B978- Other viral agents as the cause ofdiseases classified elsewhere
Conditions
Interventions
Intervention1: Drug Intervention: Montelukast 10 mg orally once daily + standard of care (symptomatic)
4 Weeks
Control Intervention1: Placebo: Placebo + Standard of care treatment (symptomatic)
Sponsors
Indian Council Medical Research
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age more than 18 years 2. Confirmed dengue fever (NS 1 positive)
Exclusion criteria
Exclusion criteria: 1. Presence of warning sign or features of severe dengue 2. Patients with concurrent other cause of fever 3. Known leukemia/bleeding disorder like ITP 4. Patients taking steroids 5. Already on montelukast for other indication 6. Pregnancy/lactation 7. Unable to take medicine by mouth 8. Refusal to give consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of warning signs and severe disease in patients with dengue fever who receive Montelukast compared to those who receive a placebo.Timepoint: 5 days | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Duration of fever in patients with dengue fever who receive Montelukast compared to those who receive a placebo. 2. Hospitalization rates in patients with dengue fever who receive Montelukast compared to those who receive a placebo. 3. Mortality rates in patients with dengue fever who receive Montelukast compared to those who receive a placebo. 4. Adverse events related to Montelukast treatment in patients with dengue fever. Timepoint: 3,6,12,24,36 months | — |
Countries
India
Contacts
Public ContactDr MANISH SONEJA
AIIMS, New Delhi
Outcome results
None listed